239 related articles for article (PubMed ID: 22525395)
1. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.
MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
Allergy Asthma Proc; 2012; 33(2):178-85. PubMed ID: 22525395
[TBL] [Abstract][Full Text] [Related]
2. Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.
Bernstein JA; Shea EP; Koester J; Iarrobino R; Pullman WE
Allergy; 2012 Sep; 67(9):1173-80. PubMed ID: 22765833
[TBL] [Abstract][Full Text] [Related]
3. Use of ecallantide in pediatric hereditary angioedema.
MacGinnitie AJ; Davis-Lorton M; Stolz LE; Tachdjian R
Pediatrics; 2013 Aug; 132(2):e490-7. PubMed ID: 23878046
[TBL] [Abstract][Full Text] [Related]
4. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.
Banta E; Horn P; Craig TJ
Allergy Asthma Proc; 2011; 32(4):319-24. PubMed ID: 21781409
[TBL] [Abstract][Full Text] [Related]
5. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
Schneider L; Lumry W; Vegh A; Williams AH; Schmalbach T
J Allergy Clin Immunol; 2007 Aug; 120(2):416-22. PubMed ID: 17559913
[TBL] [Abstract][Full Text] [Related]
6. Ecallantide for treatment of acute attacks of hereditary angioedema.
Martello JL; Woytowish MR; Chambers H
Am J Health Syst Pharm; 2012 Apr; 69(8):651-7. PubMed ID: 22472866
[TBL] [Abstract][Full Text] [Related]
7. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.
Levy RJ; Lumry WR; McNeil DL; Li HH; Campion M; Horn PT; Pullman WE
Ann Allergy Asthma Immunol; 2010 Jun; 104(6):523-9. PubMed ID: 20568386
[TBL] [Abstract][Full Text] [Related]
8. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.
Stolz LE; Sheffer AL
Expert Rev Clin Immunol; 2012 Jan; 8(1):25-32. PubMed ID: 22149337
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.
Lumry WR; Bernstein JA; Li HH; MacGinnitie AJ; Riedl M; Soteres DF; Craig TJ; Campion M; Iarrobino R; Stolz LE; Pullman WE
Allergy Asthma Proc; 2013; 34(2):155-61. PubMed ID: 23484891
[TBL] [Abstract][Full Text] [Related]
10. Response time for ecallantide treatment of acute hereditary angioedema attacks.
Riedl M; Campion M; Horn PT; Pullman WE
Ann Allergy Asthma Immunol; 2010 Dec; 105(6):430-436.e2. PubMed ID: 21130380
[TBL] [Abstract][Full Text] [Related]
11. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide.
Li HH; Campion M; Craig TJ; Soteres DF; Riedl M; Lumry WR; MacGinnitie AJ; Shea EP; Bernstein JA
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):168-72. PubMed ID: 23548526
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.
Sheffer AL; MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):184-188.e2. PubMed ID: 23548529
[TBL] [Abstract][Full Text] [Related]
13. Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.
Stolz LE; Horn PT
Drugs Today (Barc); 2010 Aug; 46(8):547-55. PubMed ID: 20830315
[TBL] [Abstract][Full Text] [Related]
14. Ecallantide: in acute hereditary angioedema.
Garnock-Jones KP
Drugs; 2010 Jul; 70(11):1423-31. PubMed ID: 20614949
[TBL] [Abstract][Full Text] [Related]
15. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.
Sheffer AL; Campion M; Levy RJ; Li HH; Horn PT; Pullman WE
J Allergy Clin Immunol; 2011 Jul; 128(1):153-159.e4. PubMed ID: 21481442
[TBL] [Abstract][Full Text] [Related]
16. New therapies for hereditary angioedema: disease outlook changes dramatically.
Frank MM; Jiang H
J Allergy Clin Immunol; 2008 Jan; 121(1):272-80. PubMed ID: 18206518
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic approaches in hereditary angioedema.
Antoniu SA
Clin Rev Allergy Immunol; 2011 Aug; 41(1):114-22. PubMed ID: 21279474
[TBL] [Abstract][Full Text] [Related]
18. New treatment options for acute edema attacks caused by hereditary angioedema.
Thomas MC; Shah S
Am J Health Syst Pharm; 2011 Nov; 68(22):2129-38. PubMed ID: 22058099
[TBL] [Abstract][Full Text] [Related]
19. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
Riedl M
Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
[TBL] [Abstract][Full Text] [Related]
20. Ecallantide for the treatment of acute attacks in hereditary angioedema.
Cicardi M; Levy RJ; McNeil DL; Li HH; Sheffer AL; Campion M; Horn PT; Pullman WE
N Engl J Med; 2010 Aug; 363(6):523-31. PubMed ID: 20818887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]